Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지

Validation of Kinetic Method for the PKA Assay in Plasma-Derived Products

  • Shin, In-Soo (Center for Biologics Evaluation, Korea Food & Drug Administration, College of Medicine, Graduate School, Hanyang University) ;
  • Hong, Choong-Man (Center for Biologics Evaluation, Korea Food & Drug Administration) ;
  • Koh, Hyun-Chul (College of Medicine, Graduate School, Hanyang University) ;
  • Hong, Seung-Hwa (Center for Biologics Evaluation, Korea Food & Drug Administration)
  • Published : 2005.03.01
Download PDF
⟨ Previous Next ⟩

Abstract

A kinetic assay was carried out in order to compare the ability of detection for prekallikrein activator(PKA) in plasma-derived products with that of an endpoint assay and a commercial method. Using these methods, 9 human albumin preparations were assayed and compared to each other. The coefficient of variation between the Kinetic assay and the end point assay was found within 6.6% and this result showed that two methods were highly correlative and the end point assay could act as a replacement of the kinetic assay. Another important goal of this study was to investigate the reproducibility among laboratories on the kinetic assay. A collaborative study was performed to validate the kinetic method with intra and inter assays. The coefficient of variation for the intra assay of each laboratory was less than 4% and that for between individuals in the inter assay was 4.1%. These results revealed that the kinetic assay showed good reproducibility. The contents of PKA in plasma-derived products were also determined by the kinetic assay. As a result, it was found that trace amounts of PKA were present in 32 human immunoglobulin preparations, however the average concentration of PKA in 171 albumin preparations was 5.8 IU/mL.

Keywords

References

  1. Alving, B. M., Tankersley, D. L., Mason, B. L., Rossi, F., Aronson, D. L. and Finlayson, J. S., Contact-activated Factors: Contaminants of immunoglobulin preparations with coagulant and vasoactive properties. J. Lab. Clin. Med., 96, 334-346 (1980)
  2. Clements, J., Mukhtar, A., Yan, S. and Holland, A., Kallikreins and kinins in inflammatory-like events in the reproductive tract. Pharm. Res., 35(6), 537-540 (1997) https://doi.org/10.1006/phrs.1997.0183
  3. Fossum, S., Hoem, N., Gjonnass, H. and Briseid, K., Contact activation factors in plasma from women on estrogen replacement therapy after ovariohysterectomy. Thromb. Res., 93, 16170(1999)
  4. Griffin, J.H., Role of surface in surface-dependent activation of Hageman factor (blood coagulation factor XII). Proc. Natl. Acad. Sci,. 75(4), 1998-2002(1978)
  5. Heinonen, J., Peltola, K., Himberg, J.J. and Suomela, H., Hypotensive Effect of Prekallkirein activator (PKA) in plasma protein fraction (PPF). Dev. Biol. Stand., 48, 129-130(1980)
  6. Heinonen, J., Peltola, K., Himberg, J. J. and Suomela, H., Correlation of hypotensive effect of plasma protein fraction with prekallikrein activator activity: a clinical study in patients having open-heart surgery. Ann. Thorac. Surg., 33(3), 244-249 (1982) https://doi.org/10.1016/S0003-4975(10)61919-4
  7. Kaplan, A. P., Joseph, K. and Silverberg, M., Pathways for bradykinin formation and inflammatory disease. J. Allerg. Clin. Immunol., 109(2), 195-209(2002) https://doi.org/10.1067/mai.2002.121316
  8. Kaplan, A. P., Initiation of the intrinsic coagulation and fibrinolytic pathways of man: The role of surfaces, Hageman factor, prekallikrein, high molecular weight kininogen, and factor XI. Prog. Hemost. Thromb., 4, 127-175(1978)
  9. Regoli, D., Rizzi, A. and Calo, G., Pharmacology of the kallikrein-kinin system. Pharma. Res., 35(6), 513-515(1997) https://doi.org/10.1006/phrs.1997.0178
  10. Revak, S. D., Cochrane, C. G., Johnston, A. R. and Hugli, T. E., Structural changes accompanying enzymatic activation of human Hageman factor. J. Clin. Invest., 54(3), 619-627(1974) https://doi.org/10.1172/JCI107799
  11. Rob E., Van Rosevelt, R. E., Bakker, J. C., Sinclair, D. M., Damen, J. and Van Mourik, J. A., Bradykinin-mediated hypotension after infusion of plasma-protein fraction. J. Lab. Clin. Med., 100, 288-295(1982)
  12. Shin, I. S., Shim, Y. B., Hong, C. M., Koh, H. C., Lee, S. H. and Hong, S. H., An improved, reliable and practical kinetic assay for the detection of prekallikrein activator in blood products. Arch. Pharm. Res., 25(4), 505-510(2002) https://doi.org/10.1007/BF02976610
  13. Snape, T. J., Griffith, D., Vallet, L. and Wesley, E. D., The assay of prekallikrein activator in human blood products. Dev. Biol. Stand., 44, 115-120(1979)
  14. Tankersley, D. L., Fournel, M. A. and Schroeder, D. D., Kinetics of activation of prekallikrein by prekallikrein activator. Biochemistry, 19(14), 3121-3127(1980) https://doi.org/10.1021/bi00555a001
  15. Turner, P. J., Young, I. F., Marley, P. B., Herrington, R. W. and Schiff, P., Albumin solutions: Their production and quality control. Dev. Biol.. Stand., 67, 119-127(1987)
  16. Yasda, J., Ueno, G, Kuratsuka, K., Homma, R., Hara, S., Kazama, M. and Ito, H., Japanese minimum requirements for albumin preparations recent amendments and current problems. Dev. Biol. Stand., 48, 143-52(1981)